When does Bristol-Myers Squibb report earnings and why does it matter for BMY.SW stock?

Bristol-Myers Squibb reports on **05 Feb 2026**; the print matters because guidance and product-level commentary will likely drive short-term moves in BMY.SW stock and reset valuations for the next 12 months.

What are the key valuation metrics for BMY.SW stock right now?

At the after-hours price **CHF42.54**, key metrics include **EPS CHF2.33**, **PE 18.26**, dividend yield **3.50%**, and price/ sales **1.79**, reflecting solid cash flow but higher leverage versus peers.

What does the Meyka AI forecast imply for BMY.SW stock performance?

Meyka AI's model projects **CHF48.40** in 12 months, implying **+13.78%** versus **CHF42.54**; forecasts are model-based and not guarantees, and earnings outcomes can change the path materially.

How should investors position ahead of the earnings release for BMY.SW stock?

Investors can either reduce position size, use defined-risk options trades, or wait for the post-earnings reaction. Earnings add event risk; long-term holders should compare guidance to cash flow and leverage metrics.

CH Stocks

BMY.SW CHF42.54 down 4.40% after hours 03 Feb 2026: earnings due Feb 05 could shift stock

ByDanny Kontos February 3, 2026February 3, 2026

BMY.SW stock opened the after-hours session at CHF42.54, down 4.40% on heavy relative flow after the SIX close on 03 Feb 2026. The move arrives with Bristol-Myers Squibb (BMY.SW) set to report results on 05 Feb 2026, making the next two sessions critical for guidance. Key metrics: EPS CHF2.33, PE 18.26, 50/200-day average CHF43.75. Traders should watch earnings guidance, US market reaction, and short-term liquidity around the CHF42.50 level as catalysts for further price action.